Summary by Futu AI
Seelos Therapeutics, a clinical-stage biopharmaceutical company, has not declared or paid cash dividends on its common stock and does not anticipate doing so in the foreseeable future. The company's financial condition and other business factors will influence the payment of dividends. During the quarter ended December 31, 2023, Seelos issued shares of common stock to satisfy principal and interest payments under the 2021 Note. Seelos focuses on developing products for Central Nervous System (CNS) disorders and other rare disorders. Its pipeline includes SLS-002 for Acute Suicidal Ideation and Behavior in Major Depressive Disorder, which completed Phase II enrollment, and SLS-005 for Amyotrophic Lateral Sclerosis, with a data readout expected in Q1 2024. The company has temporarily paused additional spend on certain preclinical programs...Show More